1. Home
  2. MHF vs CDXS Comparison

MHF vs CDXS Comparison

Compare MHF & CDXS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Western Asset Municipal High Income Fund Inc.

MHF

Western Asset Municipal High Income Fund Inc.

HOLD

Current Price

$6.89

Market Cap

148.1M

Sector

Finance

ML Signal

HOLD

Logo Codexis Inc.

CDXS

Codexis Inc.

N/A

Current Price

$1.80

Market Cap

141.8M

Sector

Industrials

ML Signal

N/A

Company Overview

Basic Information
Metric
MHF
CDXS
Founded
1988
2002
Country
United States
United States
Employees
N/A
N/A
Industry
Finance/Investors Services
Major Chemicals
Sector
Finance
Industrials
Exchange
Nasdaq
Nasdaq
Market Cap
148.1M
141.8M
IPO Year
N/A
2010

Fundamental Metrics

Financial Performance
Metric
MHF
CDXS
Price
$6.89
$1.80
Analyst Decision
Analyst Count
0
0
Target Price
N/A
N/A
AVG Volume (30 Days)
57.2K
805.0K
Earning Date
01-01-0001
02-26-2026
Dividend Yield
4.29%
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
$52,932,000.00
Revenue This Year
N/A
$15.64
Revenue Next Year
N/A
$5.23
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$5.92
$1.52
52 Week High
$6.79
$5.43

Technical Indicators

Market Signals
Indicator
MHF
CDXS
Relative Strength Index (RSI) 41.67 56.97
Support Level $6.88 $1.61
Resistance Level $7.02 $1.74
Average True Range (ATR) 0.06 0.08
MACD 0.00 0.02
Stochastic Oscillator 24.67 97.87

Price Performance

Historical Comparison
MHF
CDXS

About MHF Western Asset Municipal High Income Fund Inc.

Western Asset Municipal High Income Fund Inc is a diversified closed-end management investment company. The company's objective is to seek high current income exempt from federal income taxes. It invests predominantly in intermediate and long-term municipal debt securities issued by state and local governments.

About CDXS Codexis Inc.

Codexis Inc is a provider of enzymatic solutions for efficient and scalable therapeutics manufacturing that leverages its proprietary CodeEvolver technology platform to discover, develop, and enhance novel, high-performance enzymes. Codexis enzymes solve challenges associated with small molecule pharmaceuticals manufacturing and nucleic acid synthesis. The Company is currently developing its proprietary ECO Synthesis manufacturing platform to enable the scaled manufacture of RNAi therapeutics through an enzymatic route. Codexis' enzymes can drive improvements such as higher yields, reduced energy usage and waste generation, improved efficiency in manufacturing and greater sensitivity in genomic and diagnostic applications. Geographically, it derives maximum revenue from the Americas.

Share on Social Networks: